Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Leigh Ellis

Showing results (11-20 of 70) with videos related to

Pageof 7
Sort By:
The Prostate|July 29, 2011
Development of a castrate resistant transplant tumor model of prostate cancerLeigh Ellis, Kristin Lehet, Swathi Ramakrishnan, et al.
Plos One|July 30, 2014
Inhibition of Hsp90 augments docetaxel therapy in castrate resistant prostate cancerShengYu Ku, Elena Lasorsa, Remi Adelaiye, et al.
Advances in Experimental Medicine and Biology|January 5, 2020
The Role of RB in Prostate Cancer ProgressionDeborah L Burkhart, Katherine L Morel, Anjali V Sheahan, et al.
Oncotarget|October 29, 2013
Combinatorial antitumor effect of HDAC and the PI3K-Akt-mTOR pathway inhibition in a Pten defecient model of prostate cancerLeigh Ellis, Sheng Yu Ku, Swathi Ramakrishnan, et al.
Oncoscience|March 15, 2016
EZH2 inhibition re-sensitizes multidrug resistant B-cell lymphomas to etoposide mediated apoptosisMatthew Smonskey, Elena Lasorsa, Spencer Rosario, et al.
Molecular Cancer Therapeutics|November 16, 2011
Vascular disruption in combination with mTOR inhibition in renal cell carcinomaLeigh Ellis, Preeti Shah, Hans Hammers, et al.
Molecular Cancer Research : MCR|April 17, 2021
NF-κB Blockade with Oral Administration of Dimethylaminoparthenolide (DMAPT), Delays Prostate Cancer Resistance to Androgen Receptor (AR) Inhibition and Inhibits AR VariantsKatherine L Morel, Anis A Hamid, John G Clohessy, et al.
American Journal of Clinical and Experimental Urology|January 13, 2023
Activation of ONECUT2 by RB1 loss in castration-resistant prostate cancerChen Qian, Qian Yang, Stephen J Freedland, et al.
Journal of Bone Oncology|September 1, 2021
Use of FVB Myc-CaP cells as an immune competent, androgen receptor positive, mouse model of prostate cancer bone metastasisYu Wang, Mackenzie K Herroon, Steven P Zielske, et al.
Plos One|February 4, 2012
Class I histone deacetylase inhibitor entinostat suppresses regulatory T cells and enhances immunotherapies in renal and prostate cancer modelsLi Shen, Michael Ciesielski, Swathi Ramakrishnan, et al.
Pageof 7

Showing results (11-20 of 70) with videos related to

Sort By:
Pageof 7
The Prostate|July 29, 2011
Development of a castrate resistant transplant tumor model of prostate cancerLeigh Ellis, Kristin Lehet, Swathi Ramakrishnan, et al.
Plos One|July 30, 2014
Inhibition of Hsp90 augments docetaxel therapy in castrate resistant prostate cancerShengYu Ku, Elena Lasorsa, Remi Adelaiye, et al.
Advances in Experimental Medicine and Biology|January 5, 2020
The Role of RB in Prostate Cancer ProgressionDeborah L Burkhart, Katherine L Morel, Anjali V Sheahan, et al.
Oncotarget|October 29, 2013
Combinatorial antitumor effect of HDAC and the PI3K-Akt-mTOR pathway inhibition in a Pten defecient model of prostate cancerLeigh Ellis, Sheng Yu Ku, Swathi Ramakrishnan, et al.
Oncoscience|March 15, 2016
EZH2 inhibition re-sensitizes multidrug resistant B-cell lymphomas to etoposide mediated apoptosisMatthew Smonskey, Elena Lasorsa, Spencer Rosario, et al.
Molecular Cancer Therapeutics|November 16, 2011
Vascular disruption in combination with mTOR inhibition in renal cell carcinomaLeigh Ellis, Preeti Shah, Hans Hammers, et al.
Molecular Cancer Research : MCR|April 17, 2021
NF-κB Blockade with Oral Administration of Dimethylaminoparthenolide (DMAPT), Delays Prostate Cancer Resistance to Androgen Receptor (AR) Inhibition and Inhibits AR VariantsKatherine L Morel, Anis A Hamid, John G Clohessy, et al.
American Journal of Clinical and Experimental Urology|January 13, 2023
Activation of ONECUT2 by RB1 loss in castration-resistant prostate cancerChen Qian, Qian Yang, Stephen J Freedland, et al.
Journal of Bone Oncology|September 1, 2021
Use of FVB Myc-CaP cells as an immune competent, androgen receptor positive, mouse model of prostate cancer bone metastasisYu Wang, Mackenzie K Herroon, Steven P Zielske, et al.
Plos One|February 4, 2012
Class I histone deacetylase inhibitor entinostat suppresses regulatory T cells and enhances immunotherapies in renal and prostate cancer modelsLi Shen, Michael Ciesielski, Swathi Ramakrishnan, et al.
Pageof 7